# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Leonid Timashev reiterates Legend Biotech (NASDAQ:LEGN) with a Outperform and maintains $86 price target.
Scotiabank analyst George Farmer maintains Legend Biotech (NASDAQ:LEGN) with a Sector Outperform and raises the price target...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $73 price t...
Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.38...
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With...